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Abstract
Background: Little information exists regarding the burden of HIV among tuberculosis patients in India, and no population-
based surveys have been previously reported. A community-based HIV prevalence survey was conducted among
tuberculosis patients treated by the national tuberculosis control programme to evaluate the HIV prevalence among
tuberculosis patients in India.
Methodology/Principal Findings: Fifteen districts (total population: 40.2 million) across 8 states were stratified by HIV
prevalence in antenatal clinic HIV surveillance sites and randomly selected. From December 2006 to May 2007, remnant
serum was collected from patients’ clinical specimens taken after 2 months of anti-tuberculosis treatment and subjected to
anonymous, unlinked HIV testing. Specimens were obtained and successfully tested for 5,995 (73%) of 8,217 tuberculosis
patients eligible for the survey. HIV prevalence ranged widely among the 15 surveyed districts, from 1% in Koch Bihar, West
Bengal, to 13.8% in Guntur, Andhra Pradesh. HIV infection was 1.3 times more likely among male TB patients than among
female patients. Relative to smear-positive tuberculosis, HIV infection was 1.4 times more likely among smear-negative
patients and 1.3 times more likely among extrapulmonary patients. In 4 higher-HIV prevalence districts, which had been
previously surveyed in 2005–2006, no significant change in HIV prevalence was detected.
Conclusions: The burden of HIV among tuberculosis patients varies widely in India. Programme efforts to
implement comprehensive TB-HIV services should be targeted to areas with the highest HIV burden. Surveillance
through routine reporting or special surveys is necessary to detect areas requiring intensification of TB-HIV collaborative
activities.
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Introduction
The harmful synergy between the HIV and tuberculosis
epidemics has added dramatically to the suffering and death
caused by each disease alone[1]. HIV-infection is among the
strongest risk factors for progression of latent tuberculosis infection
to active disease[2,3]. HIV surveillance among tuberculosis
patients allows assessment of the impact of the HIV epidemic on
the tuberculosis situation and facilitates planning of collaborative
activities between HIV/AIDS and tuberculosis programmes.
Furthermore, surveillance provides information necessary to
monitor the effectiveness of joint strategies aimed at reducing
the impact of HIV among tuberculosis patients[4].
India has the highest total burden of tuberculosis in the world—
with an estimated 1.85 million incident cases in 2005[5]. The
effect, however, of the HIV epidemic on TB in India is not
understood by most. The National AIDS Control Organization
(NACO) estimates that 2.47 million persons (approximately 0.36%
of the adult population) were living with HIV infection in India in
2006. The distribution of HIV, however, is highly heterogeneous,
and HIV prevalence may be increasing in some areas, while stable
or decreasing in others[6]. For several years, anecdotal reports
from referral institutions in India have suggested that HIV
prevalence is high among TB patients[7–14]. These findings
cannot be generalized to tuberculosis patients diagnosed and
treated through community-based services.
Tuberculosis control services in India are provided through
the Revised National Tuberculosis Control Programme (RNTCP),
which in 2005 reported and treated 1.16 million incident
tuberculosis cases[15]. The first round of population-based
surveillance of HIV infection in tuberculosis patients using
RNTCP services was conducted in 2005–6 in four districts with
high HIV-prevalence in South India[16]. To guide collaborative
TB-HIV activities, the government of India expanded the
HIV surveillance of tuberculosis patients to 15 districts during
2006–2007, covering districts in different stages of the HIV
epidemic.
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District selection
Operational and supervision constraints limited the total
number of districts surveyed to 15. Sentinel districts were selected
with the a priori understanding that district results could not be
generalized to the state or national level. District selection was
stratified by antenatal clinic (ANC) HIV seroprevalence using
sentinel surveillance data to allow future trend evaluation in
settings with different HIV/AIDS epidemiological situations[16].
We selected 5 of 72 districts with a mean 2003–2005 antenatal
HIV seroprevalence of 0–0.5%, and 5 of 59 districts with a mean
2003–2005 antenatal HIV seroprevalence of 0.51–1.0% (Fig. 1).
Among the 79 districts with an ANC HIV seroprevalence .1%, 1
district was randomly selected in addition to 4 districts previously
chosen randomly for the 2005–2006 survey; these 4 were included
again for the purpose of trend analysis. The total 2006 population
of the districts selected was 40.2 million persons.
Patient eligibility and enrollment
All notified new cases of tuberculosis, (pulmonary and extrapul-
monary) in persons $14 years old were eligible. Eligibility was
limited to patients newly diagnosed with tuberculosis to preclude the
possibility of double-counting cases. Patients were selected consec-
Figure 1. Districts selected for the survey. District selection stratified by mean HIV seroprevalence in antenatal clinic (ANC) surveillance sites,
2003–2005. Districts shaded blue had mean 2003–2005 ANC HIV seroprevalence 0–0.5%, yellow districts had ANC HIV seroprevalence 0.51–1.0%, and
red districts had ANC HIV seroprevalence .1.0%. The districts of Davangere, Guntur, Nasik, and Tiruvanamalai were selected in the previous years’
survey, and were purposively selected again for trend analysis.
doi:10.1371/journal.pone.0002970.g001
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located in public clinics and hospitals in each district. Patients were
enrolled at their routine 2-month follow up visit to the DMC as this
enabled the inclusion of smear-negative and extrapulmonary TB
cases. Enrollment at the follow-up visit also ensured that only
confirmed tuberculosis cases were included.Ofthe460 DMCsinthe
survey districts, 150 DMCs with ,10 tuberculosis cases per quarter
were excluded from the survey for operational considerations.
A sample size of 400 tuberculosis patients per district was
selected, based on the minimum number of patients needed to
detect a prevalence of at least 5% HIV infection, with 95%
confidence and 40% precision.
HIV testing
At the time of their 2-month follow-up visit, all eligible
tuberculosis patients were offered a free, voluntary liver function
test (LFT). If patients verbally consented to specimen collection for
LFT, samples were collected at the DMC; refusals were
documented. LFT test results were communicated back to the
provider. Remnant serum specimens were used for unlinked,
anonymous HIV testing.
To ensure uniform implementation across all 15 districts,
standard training material and operating procedures were
developed, and trainings conducted at all sites by a single training
team. Supervision checklists were developed for local programme
supervisors, and progress was tracked by bi-weekly reports.
Ethical issues
This surveillance activity was conducted after review and
approval of NACO and the Central Tuberculosis Division,
Directorate General of Health Services, Ministry of Health and
Family Welfare, Government of India. The surveillance activity
was justified as necessary to develop and guide national TB and
HIV programme policies. It was felt that the information could not
be accurately obtained by surveillance methods other than
anonymous, unlinked testing. Due to the anonymous, unlinked
design, the activity relied on testing of remnant specimens
collected for another clinical purpose. HIV results were not
individually identifiable, and hence could not be returned. Patients
were not asked to provide specific consent for the anonymous,
unlinked HIV testing of their specimen remnants. However, free
voluntary HIV counseling and testing was provided for all TB
patients as per national guidelines[17], and all HIV-infected
patients were eligible for free care, including anti-retroviral
treatment, through the National AIDS Control Programme. This
approach to HIV surveillance among TB patients has been
included in WHO guidelines[4] and is in line with current
National AIDS programme HIV surveillance strategy.
Laboratory methods
The DMC laboratory technicians received special training on
blood sample collection, serum separation, storage and the
transportation of samples to testing sites. HIV testing was
conducted by a quality-assured laboratory network established
by NACO for HIV surveillance. An unidentified refrigerated
aliquot of serum was transported from the collection site to the
designated laboratory within 7 days of collection. Initial HIV
testing was performed by the Enzyme-Linked ImmunoSorbent
Assay (ELISA). Specimens reactive on the first assay were retested
with a rapid assay, and results were interpreted as HIV-positive
only if both tests were reactive. All the HIV-reactive serum and
5% of the HIV-negative serum samples were sent to national
reference laboratories for re-testing per routine NACO quality
assurance procedures.
Data collection & analysis
Data were double entered and validated against the original test
reports, and analyzed with EpiData v1.1 (EpiData Association,
Odense, Denmark). We calculated the HIV prevalence among all
TB patients in each district. We also calculated a standardized
HIV prevalence rate to account for the under-enrollment of
smear-negative and extrapulmonary tuberculosis cases in several
districts. To standardize the HIV prevalence rate, the tuberculosis-
type specific HIV prevalence was applied to the number of eligible
tuberculosis cases for each type of tuberculosis for each district.
This tuberculosis-type standardized HIV prevalence was com-
pared to the non standardized prevalence. Proportions were
compared using a chi-square test, or Fisher’s exact test if any




Of the 9,450 new tuberculosis patients registered during the
survey period, 1,274 were seen at excluded microscopy centers
and classified as ineligible (Fig. 2). Excluding 49 patients who
transferred out of the survey area before specimen collection,
8,217 tuberculosis patients in the 15 districts fulfilled the eligibility
criteria. Of these 2,166 were not included—most commonly
because of treatment interruptions (959 persons, 11.7%) or refusal
(646 persons, 7.8%). Serum specimens were collected from 6,051
(73.6%) of the eligible tuberculosis patients, and HIV test results
were available for 5,995 (73.0%) of the eligible patients.
Patient characteristics
Among the 5,995 patients tested in the survey, the median age
was 35 years (range 14–95 years), and 3998 (69.4%) were male
patients. No significant difference existed between districts in the
age or sex distribution of tested patients. Overall, 3395 (56.6%) of
tested patients were smear-positive, 1725 (28.8%) were smear-
negative, and 866 (14.4%) had only extra-pulmonary tuberculosis;
type of tuberculosis was not reported for 9 (0.2%) patients.
Compared to patients not included in the survey, no significant
difference existed in the distribution of age or sex. However, in 7
districts, there was a higher proportion of smear-negative and/or
extrapulmonary tuberculosis among the patients who were not
included.
HIV prevalence results
HIV infection was detected in tuberculosis patients in all 15
surveyed districts. HIV seroprevalence among tuberculosis
patients ranged widely, from 1% in Koch Bihar to 13.8% in
Guntur (Table 1). In the aggregate population of tested patients
across all districts, HIV seroprevalence in tuberculosis patients was
highest in the groups of those aged 25–34 years (11.0%) and 35–
44 years (10.6%). However, instances of HIV infection were
observed in tuberculosis patients up to 70 years. HIV seroprev-
alence was higher among male tuberculosis patients than female
tuberculosis patients (8.4% vs. 5.6%, relative risk [RR] 1.28, 95%
confidence interval [CI] 1.04–1.59). Compared to smear-positive
tuberculosis cases (5.8% HIV seroprevalence), the survey detected
a higher HIV prevalence among smear-negative (8%; RR: 1.41,
95% CI, 1.13–1.76) and extrapulmonary tuberculosis cases (7.4%;
RR: 1.30, 95% CI, 0.96–1.72). In four districts where the survey
was also conducted during 2005–2006, no significant difference in
HIV prevalence in tuberculosis patients was observed over 2 years
(Table 2).
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doi:10.1371/journal.pone.0002970.g002
Table 1. HIV seroprevalence among tuberculosis patients in 15 districts in India, 2006–2007.
State District HIV stratification
a Tested HIV-positive HIV seroprevalence 95% Confidence Interval
Andhra Pradesh Guntur High 400 55 13.8% 10.7–17.5%
Vizianagaram Medium 399 26 6.5% 4.5–9.4%
Gujarat Junagadh Low 399 16 4.0% 2.5–6.4%
Vadodara Low 399 10 2.5% 1.4–4.6%
Karnataka Davanagere High 400 37 9.3% 6.8–12.5%
Kerala Thrissur Medium 402 22 5.5% 3.6–8.2%
Maharashtra Dhule Medium 400 44 11.0% 8.3–14.5
Nashik High 400 16 4.0% 2.5–6.4%
Parbhani Medium 400 48 12.0% 9.2–15.6%
Raigarh Medium 401 33 8.2% 5.9–11.3%
Rajasthan Jodhpur Low 400 11 2.8% 1.5–4.9%
Tamil Nadu Tiruvanamalai High 399 37 9.3% 6.8–12.5%
Villipuram Medium 401 31 7.7% 5.5–10.8%
West Bengal Koch Bihar Low 394 4 1.0% 0.4–2.6%
Uttar Dinajpur Low 401 9 2.2% 1.2–4.2%
aDistricts stratified by mean HIV seroprevalence in antenatal clinic (ANC) surveillance sites, 2003–2005. Low ,0.5%, Medium=0.51–1.0%, High .1.0%.
doi:10.1371/journal.pone.0002970.t001
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patients tested and those not included in the survey led to an
underestimation of HIV prevalence in tuberculosis patients, we
compared the calculated prevalence with the tuberculosis-type
standardized HIV prevalence in each district. There were no
significant differences between standardized and nonstandardized
HIV prevalence in any district.
Discussion
This survey represents the first reported HIV-prevalence data
from a community-based survey among tuberculosis patients in
India. The survey identified a wide distribution of HIV
seroprevalence among tuberculosis patients, ranging from 1% to
13.8% in the 15 surveyed districts. These data suggest that HIV-
infection among tuberculosis patients may exist everywhere, but
the wide distribution in severity will create operational challenges
for the design and implementation of collaborative TB-HIV
interventions.
This survey has important implications for the Indian
tuberculosis and HIV control programmes. The prevalence of
HIV among tuberculosis patients exceeded 5% in 8 of 9 districts
from states considered to have high HIV prevalence (Andhra
Pradesh, Karnataka, Maharashtra, and Tamil Nadu). Five percent
is the threshold at which WHO has recommended intensified
interventions to address TB-HIV, including voluntary HIV testing
of all tuberculosis patients[19]. This finding supports the recent
decision of the Ministry of Health and Family Welfare to adopt the
policy of routinely offering voluntary HIV counseling and testing
to all tuberculosis patients in states with higher HIV burdens[20].
Conversely, in low-prevalence areas where more than 95% of
TB patients are HIV-negative, a uniform policy of testing all
tuberculosis patients for HIV may generate substantial operational
difficulties while yielding little improvement in health outcomes.
Quality-assured HIV counseling and testing services are usually
only available in urban sections in low-prevalence areas[21]. Until
HIV testing services are made available at the sub-district level to
match the widespread availability of tuberculosis services, in these
settings the preferable course may be selective referral, based on
risk factors or clinical signs of HIV infection.
In the aggregate population of all tested patients, a few general
trends of HIV epidemiology among tuberculosis patients emerged.
HIV-infection was more common in tuberculosis patients aged
25–44 years, but was found in all age groups in the surveyed
population and in patients up to age 70 years. In tuberculosis
patients, HIV-infection was more common among males patients
than female patients, as has been observed in the general
population[6]. Also, compared to new smear-positive pulmonary
TB patients, HIV-infection was 1.4 and 1.3 times more common
among smear-negative and extrapulmonary patients respectively.
These observations are consistent with what is known about HIV
epidemiology in general in India and the clinical presentation of
tuberculosis in HIV-infected persons[6,22].
In the 4 districts with repeat surveys, no significant change was
detected in HIV prevalence among tuberculosis patients. This
finding is reassuring and adds to the data suggesting stability in the
HIV epidemic in India. However, these 4 districts were considered
to have high HIV prevalence as judged by the mean 2003–2005
ANC HIV seroprevalence .1% at sentinel surveillance sites. No
trend data is available for areas with lower HIV prevalence.
What is the optimal future method of conducting HIV
surveillance among TB patients in India? Given the epidemiolog-
ical diversity demonstrated in this survey and the geographical
vastness of India, special surveys may not be able to generate the
necessary local information needed to guide tuberculosis and HIV
programmes. Instead, routine recording and reporting of HIV
status of tuberculosis patients by the tuberculosis programme is
probably the preferable surveillance option in high HIV
prevalence states. Periodic HIV surveillance among tuberculosis
patients may still have some value in low HIV prevalence states to
detect when intensification of TB-HIV collaborative activities is
indicated, or as a sentinel activity to detect early increases in
community HIV seroprevalence.
Limitations
This survey was not intended to be generalized to the state or
nationallevels.Becauseofanumberoflimitations,thissurveyshould
be considered cautiously as a minimum estimate, and the actual
prevalence of HIV infection among all tuberculosis patients in these
districts may be slightly higher. First, only new tuberculosis patients
were enrolled to limit the possibility of double-counting persons who
failed treatment and were re-registered as re-treatment cases.
Recurrent tuberculosis is known to be more common among
HIV-infected persons, and this may lead to some underestimation of
HIV prevalence among all tuberculosis patients[23]. However, in
the 15 districts surveyed, only 12% of patients in the 1st and 2nd
quarter of 2007 were registered as re-treatment cases; unless the
difference in HIV prevalence between new and re-treatment
tuberculosis cases were very large, this is not likely to have
substantially influenced our results.
Specimens were collected from patients during the 2
nd-month
clinical evaluation. There were 175 patients, however, who died and
959 who interrupted treatment during the first 2 months and could
not be included. Death during tuberculosis treatment is known to be
higher among HIV-infected persons than non–HIV-infected
persons. It is unknown if tuberculosis treatment interruptions are
more common among HIV-infected persons than non–HIV-
infected persons in India, but some deaths may have been classified
as treatment interruptions. If the prevalence of HIV infection were
greater in this unincluded group, then we may have underestimated
the HIV prevalence among tuberculosis patients in this survey.
Only cases that were notified to the RNTCP were included in
the survey. Limited data about patients treated outside the
government programme is available to estimate the burden of
tuberculosis or the HIV prevalence among those with tuberculosis.
No data suggests that the HIV prevalence would be substantially
different than those notified to the tuberculosis programme,
particularly with the large-scale involvement of public and private
Table 2. Trends in HIV seroprevalence among tuberculosis






positive Percent 95% CI
Davangere 2005–2006 400 38 9.5% 7.0–12.8%
2006–2007 400 37 9.3% 6.8–12.5%
Guntur 2005–2006 400 64 16.0% 12.7–19.9%
2006–2007 400 55 13.8% 10.7–17.5%
Nashik 2005–2006 400 17 4.3% 2.7–6.7%
2006–2007 400 16 4.0% 2.5–6.4%
Thiruvanamalai 2005–2006 400 25 6.3% 4.3–9.1%
2006–2007 400 37 9.3% 6.8–12.5%
doi:10.1371/journal.pone.0002970.t002
HIV among TB Patients in India
PLoS ONE | www.plosone.org 5 August 2008 | Volume 3 | Issue 8 | e2970medical colleges in the tuberculosis programme over the past
2 years[24].
Conclusions
The survey demonstrated a diverse distribution of HIV infection
among tuberculosis patients in India, which supports targeted
programme efforts. Periodic surveys may have a role in areas with
low HIV prevalence as a tool to help detect emerging pockets of
HIV infection and guide future HIV prevention efforts. Future
surveillance of HIV infection in tuberculosis patients in India may
be based on routine data collected by the tuberculosis programme
recording and recording system, coupled with programme efforts
to improve the uptake of HIV counseling and testing in this patient
population. The association between HIV prevalence among
tuberculosis patients, HIV surveillance at antenatal clinic, and
community-based surveys requires further investigation.
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